The single-blastomere technology uses a one cell biopsy approach similar to pre-implantation genetic diagnosis (NYSEARCA:PGD), which is widely used in the in vitro fertilization (IVF) process and does not interfere with the embryo’s developmental potential.
- The stem cells generated using this approach are healthy, completely normal and differentiate into all the cell types of the human body, including insulin-producing cells, blood cells, beating heart cells, cartilage and other cell types of therapeutic importance;
- The safety record for one cell biopsy as part of PGD now has a 15 year track record, and is carried out routinely as part of IVF processes around the world.
The Bottom Line: This patent issuance represents its single-blastomere technology which ”could” help accelerate progress on deriving embryonic stem cells to meet the regulatory standards of the European Medicines Agency and the US FDA. It has been stated that, using the single-blastomere technology; ACTC.OB might be able to develop collaborations for creating banks of these cells using this proprietary technique. ACTC.OB has150 patents and patent applications related to stem cell therapy and regenerative medicine.